Novartis Ag

Zhengtian Yu

Yuan Mi

Ling Li

Xiang-Ju Justin Gu

Martin Sendzik

Lei Li

Qiong Zhang

Long Wang

Wei Qi

Man Zhang

Yongfeng Sun

Ho Man Chan

Hailong Zhang

Ji Yue Zhang

Ji Yue (Jeff) Zhang

Kehao Zhao

Xingnian Fu

Yue Ping Li

Feng He

Lei Liu

Guoliang Xun

Lei Jiang

Julien Papillon

Miao Dai

Xiaoxia Yan

Fang Liang

Michael Dore

Yao-Chang Xu

Counde Oyang

Xuan Dai

Kun Chin Liu

Wei (Vicky) Qi

Sing Yeung Frankie Mak

Ying Huang

The invention disclosed herein relates to aza-quinoline compounds of Formula (I), pharmaceutical compositions comprising such compounds; and the use of such compounds for treating a disease or condition mediated by Enhancer of Zeste Homolog(EZH), Polycomb Repressive Complex(PRC), or a combination thereof.

Quinoline compounds and compositions for inhibiting EZH2

A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R, R, R, R, R, and n are as defined herein.

Triazolopyrimidine compounds and uses thereof

A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein A, R, Rand Rare as defined herein.

Triazolopyridine compounds and uses thereof

A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein A, R, R, R, and Rare as defined herein.

Imidazolepyridine compounds and uses thereof

The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

Heterocyclic oxime compounds

The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I). 

Heterocyclic hydrazone compounds

Growing community of inventors

Shanghai, China

Zhengtian Yu